- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-2-3-mer
- Ligands
- 11 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 25 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.12: 4 residues within 4Å:- Chain B: N.267, E.268, N.269
- Chain E: K.545
Ligand excluded by PLIPNAG.13: 4 residues within 4Å:- Chain B: N.318, P.566, Q.567, T.568
Ligand excluded by PLIPNAG.14: 4 residues within 4Å:- Chain B: F.325, G.326, N.330, V.354
Ligand excluded by PLIPNAG.15: 1 residues within 4Å:- Chain B: N.603
Ligand excluded by PLIPNAG.16: 1 residues within 4Å:- Chain B: N.644
Ligand excluded by PLIPNAG.17: 2 residues within 4Å:- Chain B: N.696, G.1118
Ligand excluded by PLIPNAG.18: 4 residues within 4Å:- Chain B: A.693, E.1059, K.1060, N.1061
Ligand excluded by PLIPNAG.19: 2 residues within 4Å:- Chain C: T.95, N.221
Ligand excluded by PLIPNAG.20: 1 residues within 4Å:- Chain C: N.269
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain C: N.318, P.566, Q.567
Ligand excluded by PLIPNAG.22: 6 residues within 4Å:- Chain C: F.325, G.326, F.329, N.330, V.354, L.355
Ligand excluded by PLIPNAG.23: 1 residues within 4Å:- Chain C: N.590
Ligand excluded by PLIPNAG.24: 2 residues within 4Å:- Chain C: N.603, T.605
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain C: H.642, N.644
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain C: N.696, G.1118
Ligand excluded by PLIPNAG.27: 4 residues within 4Å:- Chain C: T.703, N.704, L.909, Q.1058
Ligand excluded by PLIPNAG.28: 4 residues within 4Å:- Chain C: A.693, E.1059, K.1060, N.1061
Ligand excluded by PLIPNAG.29: 1 residues within 4Å:- Chain E: N.48
Ligand excluded by PLIPNAG.30: 5 residues within 4Å:- Chain E: N.109, T.111, N.112, V.114, F.144
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain E: N.267, N.269
Ligand excluded by PLIPNAG.32: 4 residues within 4Å:- Chain E: N.318, P.566, Q.567, L.569
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain E: N.603, Q.631
Ligand excluded by PLIPNAG.34: 1 residues within 4Å:- Chain E: N.644
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain B: D.783
- Chain E: N.696, G.1118
Ligand excluded by PLIPNAG.36: 4 residues within 4Å:- Chain E: A.693, E.1059, K.1060, N.1061
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ye, G. et al., Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19. J.Virol. (2023)
- Release Date
- 2024-01-24
- Peptides
- Nanosota-3: AD
Spike glycoprotein: BCE - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
ED
CB
AC
BE
D
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-2-3-mer
- Ligands
- 11 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 25 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ye, G. et al., Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19. J.Virol. (2023)
- Release Date
- 2024-01-24
- Peptides
- Nanosota-3: AD
Spike glycoprotein: BCE - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
ED
CB
AC
BE
D